杭州美迪凯光电科技股份有限公司 证券代码：688079 证券简称：美迪凯 公告编号：2025-038 关于回购注销部分限制性股票及注销部分股票期权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 杭州美迪凯光电科技股份有限公司（以下简称"公司"）于 2025 年 10 月 30 日召开第三届董事会第六次会议，审议通过《关于回购注销部分限制性股票及注销 部分股票期权的议案》。鉴于公司《2024 年股票期权与限制性股票激励计划》（以 下简称 "《激励计划》"）中首次授予的部分激励对象因个人原因离职，公司决 定回购注销其已获授但尚未解除限售的限制性股票 32,000 股，注销其已获授但尚 未行权的股票期权 32,000 份。具体情况如下： 一、本激励计划已履行的相关程序和信息披露情况 （一）2024 年 9 月 27 日，公司召开第二届董事会第十八次会议，审议通过 《关于公司〈2024 年股票期权与限制性股票激励计划（草案）〉及其摘要的议案》 《关于公司〈2024 年股票期权与限制性股票激励计划实施考核管理办法〉的议案》 《关 ...

重要内容提示： 杭州美迪凯光电科技股份有限公司（以下简称"公司"）于 2025 年 10 月 30 日召开第三届董事会第六次会议，审议通过了《关于 2024 年股票期权与限制性股 票激励计划首次授予股票期权第一个行权期行权条件成就的议案》，认为公司 《2024 年股票期权激励计划（草案）》（以下简称"《激励计划》"或"本激励 计划"）首次授予股票期权第一个行权期的行权条件已成就，同意符合行权条件的 339名激励对象在规定的行权期内采取自主行权的方式行权。现将有关事项说明如 下： 一、股权激励计划批准及实施情况 （一）股票期权激励计划方案及履行程序 1、2024年9月27日，公司召开第二届董事会第十八次会议，审议通过《关于公 司〈2024年股票期权与限制性股票激励计划（草案）〉及其摘要的议案》《关于公 司〈2024 年股票期权与限制性股票激励计划实施考核管理办法〉的议案》《关于 提请股东大会授权董事会办理公司2024年股票期权与限制性股票激励计划有关事项 的议案》。 证券代码：688079 证券简称：美迪凯 公告编号：2025-039 杭州美迪凯光电科技股份有限公司 关于2024年股票期权与限制性股票激励计划首 ...

证券代码：688079 证券简称：美迪凯 公告编号：2025-040 杭州美迪凯光电科技股份有限公司 关于2024 年股票期权与限制性股票激励计划 首次授予股票期权第一个行权期 采用自主行权的提示性公告 一、2024 年股票期权与限制性股票激励计划首次授予股票期权第一个行权期行权 安排 本次行权的具体情况如下： （一）授予日：2024 年11月 18 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 杭州美迪凯光电科技股份有限公司（以下简称"公司"）于2025 年10月30日 召开第三届董事会第六次会议、第三届董事会薪酬与考核委员会2025年第二次会 议，审议通过了《关于公司2024年股票期权与限制性股票激励计划首次授予股票 期权第一个行权期行权条件成就的议案》。 （二）可行权数量：350.628万份 公司 2024 年股票期权与限制性股票激励计划首次授予股票期权第一个行权 期将采用自主行权的方式行权（以下简称"本次行权"），主要情况如下： 若在行权前公司有资本公积金转增股本、派送股票红利、股票拆细、配股或 缩股等事项， ...

国浩律师（上海）事务所 关 于 杭州美迪凯光电科技股份有限公司 2024 年股票期权与限制性股票激励计划 回购注销部分限制性股票及注销部分股票 期权、首次授予股票期权第一个行权期行 权条件成就、首次授予第一类限制性股票 第一个解除限售期解除限售条件成就 之 法律意见书 上海市静安区山西北路 99 号苏河湾中心 25-28 层 邮编：200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai, 200085, China 电话/Tel: +86 21 5234 1668 传真/Fax: +86 21 5243 3320 网址/Website: http://www.grandall.com.cn 二零二五年十月 国浩律师（上海）事务所 法律意见书 国浩律师（上海）事务所 关于杭州美迪凯光电科技股份有限公司 2024 年股票期权与限制性股票激励计划 回购注销部分限制性股票及注销部分股票期权、 首次授予股票期权第一个行权期行权条件成就、 首次授予第一类限制性股票第一个解除限售期解除 限售条件成就之 法律意见书 致：杭州美 ...

Group 1 - Medike (SH 688079) announced on October 30 that its third board meeting for the sixth session will be held on October 30, 2025, in a hybrid format [1] - The meeting will review the proposal regarding the company's Q3 2025 report among other documents [1] - As of the report, Medike has a market capitalization of 5 billion yuan [1] Group 2 - Multiple regions are experiencing "negative electricity prices," raising questions about why power plants are reluctant to shut down despite not making profits from selling electricity [1]

Group 1 - The core viewpoint of the article highlights that Meidike (SH 688079) reported a revenue increase of 32.04% year-on-year for the first three quarters of 2025, amounting to approximately 451 million yuan, while the net profit attributable to shareholders was a loss of about 81.77 million yuan [1] - As of the report date, Meidike's market capitalization stands at 5 billion yuan [2]

Financial Performance - The company's operating revenue for the third quarter was ¥160,422,295.11, an increase of 26.91% compared to the same period last year[4]. - The total profit for the period was -¥41,716,324.39, with a year-to-date total profit of -¥104,336,742.12[4]. - The net profit attributable to shareholders was -¥31,131,365.67 for the quarter, and -¥81,766,200.11 year-to-date[4]. - Total operating revenue for the first three quarters of 2025 reached ¥451,134,135.53, a significant increase of 32.2% compared to ¥341,670,247.32 in the same period of 2024[20]. - Net loss for the first three quarters of 2025 was ¥83,224,832.21, compared to a net loss of ¥67,733,952.86 in the same period of 2024, reflecting a deterioration in profitability[21]. - The basic and diluted earnings per share for the first three quarters of 2025 were both -¥0.21, compared to -¥0.16 in the same period of 2024, indicating a worsening earnings situation[22]. Research and Development - Research and development expenses totaled ¥34,576,056.76 for the quarter, representing 21.55% of operating revenue, an increase of 1.16 percentage points year-on-year[5]. - Research and development expenses increased to ¥100,906,161.33 in the first three quarters of 2025, up 32.3% from ¥76,365,917.87 in 2024, indicating a focus on innovation[20]. Assets and Liabilities - The company's total assets at the end of the period were ¥3,263,825,614.09, reflecting a 7.42% increase from the end of the previous year[5]. - The company's current assets reached RMB 474,606,755.55, up from RMB 412,152,468.02, indicating an increase of about 15.1%[16]. - The total liabilities increased to RMB 1,200,000,000.00, reflecting a rise from the previous period, although specific figures were not provided[15]. - Total liabilities increased to ¥1,921,873,202.26 in 2025 from ¥1,641,867,096.02 in 2024, indicating a rise in financial obligations[18]. - The company's total equity decreased to ¥1,341,952,411.83 in 2025 from ¥1,396,602,603.22 in 2024, reflecting a decline in shareholder value[18]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥97,452,480.95, an increase of 107.45% compared to the same period last year[8]. - Cash generated from operating activities was ¥434,283,553.43 for the first three quarters of 2025, compared to ¥299,591,844.11 in the same period of 2024, showing improved cash flow[24]. - Net cash flow from operating activities increased to $97,452,480.95, up from $46,975,614.85, representing a growth of 107.5% year-over-year[25]. - Total cash inflow from financing activities was $767,095,547.26, compared to $910,954,200.39 in the previous period, indicating a decrease of 15.7%[26]. - Cash and cash equivalents at the end of the period amounted to $135,750,574.57, compared to $192,625,310.11 at the end of the previous period, a decrease of 29.5%[26]. Shareholder Information - The company reported a total of 10,757 ordinary shareholders at the end of the reporting period[10]. - The largest shareholder, Hangzhou Meidike Self-Funded Investment Partnership, held 40.43% of the shares[10]. Expenses - The company experienced increased losses primarily due to higher depreciation, labor costs, and financial expenses[8]. - Total operating costs for the first three quarters of 2025 were ¥549,037,863.56, up 35.7% from ¥404,372,868.74 in the previous year[20]. - The company reported a significant increase in sales expenses, which rose to ¥7,812,790.59 in 2025 from ¥3,896,954.52 in 2024, suggesting increased marketing efforts[20].

Core Viewpoint - Meidike (688079.SH) reported a significant increase in revenue for the first half of 2025, but continued to face net losses, indicating challenges in profitability despite revenue growth [1][2]. Financial Performance - The company achieved operating revenue of 291 million yuan in the first half of 2025, representing a year-on-year increase of 35.05% compared to 215 million yuan in the same period last year [2][4]. - The net profit attributable to shareholders was a loss of 50.63 million yuan, slightly higher than the loss of 50.59 million yuan in the previous year [2][4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of 52.36 million yuan, compared to a loss of 40.21 million yuan in the same period last year [4]. - The net cash flow from operating activities was 77.16 million yuan, showing a significant increase of 55.74% from 49.54 million yuan in the previous year [4]. Historical Performance - In 2024, the company reported operating revenue of 486 million yuan, a year-on-year increase of 51.38%, but incurred a net loss of 102 million yuan, compared to a loss of 84.45 million yuan in the previous year [4]. - In 2023, the company experienced a decline in operating revenue to 321 million yuan, a decrease of 22.48%, with a net loss of 84.45 million yuan, compared to a profit of 22.09 million yuan in the previous year [4]. Capital Raising and Stock Issuance - Meidike went public on the Sci-Tech Innovation Board on March 2, 2021, issuing 100 million shares at a price of 10.19 yuan per share, raising a total of 1.022 billion yuan [5]. - The company plans to use the raised funds for the construction of an optical optoelectronic component production base and a research and development center, with excess funds allocated for repaying bank loans or supplementing working capital [5]. - On April 30, 2025, the company announced a proposal to authorize the board to issue stock to specific investors, with a total financing amount not exceeding 300 million yuan [6].

Core Viewpoint - Meidike (688079.SH) has developed mature technology in glass substrate preparation processes, including precision forming, high-precision polishing (CMP), and micron-level through holes (TGV) [1] Group 1: Technology and Production - The company has achieved mass production of high-refractive glass wafers for AR/MR applications and glass wafers for semiconductors [1] - The technology encompasses key processes such as precision forming and high-precision polishing, indicating a strong capability in advanced manufacturing [1] Group 2: Future Outlook - The company plans to continuously optimize processes and promote the industrial application of related technologies, aligning with market demands and technological trends [1]

Core Viewpoint - Medike (688079.SH) has completed the development of the production process for photomask substrates and has begun gradual sample delivery [1] Group 1: Company Developments - The company has developed a key material, photomask, which is essential for transferring circuit patterns onto wafers [1] - The quality of the photomask directly impacts the precision and yield of the photolithography process [1]